Takeda Pharmaceutical Co Ltd - Net Worth and Insider Trading

Takeda Pharmaceutical Co Ltd Net Worth

The estimated net worth of Takeda Pharmaceutical Co Ltd is at least $115 Million dollars as of 2024-12-28. Takeda Pharmaceutical Co Ltd is the 10% Owner of Day One Biopharmaceuticals Inc and owns about 6,120,124 shares of Day One Biopharmaceuticals Inc (DAWN) stock worth over $79 Million. Takeda Pharmaceutical Co Ltd is the 10% Owner of Phathom Pharmaceuticals Inc and owns about 3,755,583 shares of Phathom Pharmaceuticals Inc (PHAT) stock worth over $31 Million. Takeda Pharmaceutical Co Ltd is also the 10% Owner of Ovid Therapeutics Inc and owns about 5,750,000 shares of Ovid Therapeutics Inc (OVID) stock worth over $6 Million. Details can be seen in Takeda Pharmaceutical Co Ltd's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Takeda Pharmaceutical Co Ltd has not made any transactions after 2024-01-24 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Takeda Pharmaceutical Co Ltd

To

Takeda Pharmaceutical Co Ltd Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Takeda Pharmaceutical Co Ltd owns 14 companies in total, including Translate Bio Inc (TBIO) , BiomX Inc (PHGE.U) , and Phathom Pharmaceuticals Inc (PHAT) among others .

Click here to see the complete history of Takeda Pharmaceutical Co Ltd’s form 4 insider trades.

Insider Ownership Summary of Takeda Pharmaceutical Co Ltd

Ticker Comapny Transaction Date Type of Owner
TBIO Translate Bio Inc 2020-06-30 10 percent owner
PHGE.U BiomX Inc 2019-10-28 10 percent owner
PHAT Phathom Pharmaceuticals Inc 2024-01-24 10 percent owner
LIMIT LIMIT 2019-10-08 10 percent owner
LIMIT LIMIT 2019-07-17 10 percent owner
LIMIT LIMIT 2019-05-08 10 percent owner
LIMIT LIMIT 2018-03-19 10 percent owner
LIMIT LIMIT 2017-08-01 10 percent owner
LIMIT LIMIT 2021-10-18 10 percent owner
LIMIT LIMIT 2019-10-28 10 percent owner
LIMIT LIMIT 2021-10-06 10 percent owner
LIMIT LIMIT 2021-10-21 10 percent owner
LIMIT LIMIT 2021-12-08 10 percent owner
LIMIT LIMIT 2022-04-28 10 percent owner

Takeda Pharmaceutical Co Ltd Latest Holdings Summary

Takeda Pharmaceutical Co Ltd currently owns a total of 3 stocks. Among these stocks, Takeda Pharmaceutical Co Ltd owns 6,120,124 shares of Day One Biopharmaceuticals Inc (DAWN) as of December 8, 2021, with a value of $79 Million and a weighting of 68.45%. Takeda Pharmaceutical Co Ltd owns 3,755,583 shares of Phathom Pharmaceuticals Inc (PHAT) as of January 24, 2024, with a value of $31 Million and a weighting of 26.7%. Takeda Pharmaceutical Co Ltd also owns 5,750,000 shares of Ovid Therapeutics Inc (OVID) as of October 8, 2019, with a value of $6 Million and a weighting of 4.85%.

Latest Holdings of Takeda Pharmaceutical Co Ltd

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
DAWN Day One Biopharmaceuticals Inc 2021-12-08 6,120,124 12.87 78,765,996
PHAT Phathom Pharmaceuticals Inc 2024-01-24 3,755,583 8.18 30,720,669
OVID Ovid Therapeutics Inc 2019-10-08 5,750,000 0.97 5,578,650

Holding Weightings of Takeda Pharmaceutical Co Ltd


Takeda Pharmaceutical Co Ltd Form 4 Trading Tracker

According to the SEC Form 4 filings, Takeda Pharmaceutical Co Ltd has made a total of 2 transactions in Day One Biopharmaceuticals Inc (DAWN) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Day One Biopharmaceuticals Inc is the sale of 297,273 shares on December 8, 2021, which brought Takeda Pharmaceutical Co Ltd around $5 Million.

According to the SEC Form 4 filings, Takeda Pharmaceutical Co Ltd has made a total of 20 transactions in Phathom Pharmaceuticals Inc (PHAT) over the past 5 years, including 0 buys and 20 sells. The most-recent trade in Phathom Pharmaceuticals Inc is the sale of 3,703,703 shares on January 24, 2024, which brought Takeda Pharmaceutical Co Ltd around $30 Million.

According to the SEC Form 4 filings, Takeda Pharmaceutical Co Ltd has made a total of 0 transactions in Ovid Therapeutics Inc (OVID) over the past 5 years. The most-recent trade in Ovid Therapeutics Inc is the acquisition of 2,000,000 shares on October 8, 2019, which cost Takeda Pharmaceutical Co Ltd around $5 Million.

Insider Trading History of Takeda Pharmaceutical Co Ltd

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Takeda Pharmaceutical Co Ltd Trading Performance

GuruFocus tracks the stock performance after each of Takeda Pharmaceutical Co Ltd's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Takeda Pharmaceutical Co Ltd is 65.16%. GuruFocus also compares Takeda Pharmaceutical Co Ltd's trading performance to market benchmark return within the same time period. The performance of stocks bought by Takeda Pharmaceutical Co Ltd within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Takeda Pharmaceutical Co Ltd's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Takeda Pharmaceutical Co Ltd

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 4.51 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -2.4 LIMIT LIMIT LIMIT LIMIT LIMIT

Takeda Pharmaceutical Co Ltd Ownership Network

Ownership Network List of Takeda Pharmaceutical Co Ltd

No Data

Ownership Network Relation of Takeda Pharmaceutical Co Ltd

Insider Network Chart

Takeda Pharmaceutical Co Ltd Owned Company Details

What does Translate Bio Inc do?

Who are the key executives at Translate Bio Inc?

Takeda Pharmaceutical Co Ltd is the 10 percent owner of Translate Bio Inc. Other key executives at Translate Bio Inc include director & Chief Executive Officer & other: President Renaud Ronald C Jr , Chief Operating Officer & CLO & other: Secretary Paul D. Burgess , and 10 percent owner Shire Human Genetic Therapies, Inc. .

Translate Bio Inc (TBIO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Translate Bio Inc (TBIO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Translate Bio Inc (TBIO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Translate Bio Inc (TBIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Translate Bio Inc Insider Transactions

No Available Data

Takeda Pharmaceutical Co Ltd Mailing Address

Above is the net worth, insider trading, and ownership report for Takeda Pharmaceutical Co Ltd. You might contact Takeda Pharmaceutical Co Ltd via mailing address: 1-1, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo M0 103-8668.

Discussions on Takeda Pharmaceutical Co Ltd

No discussions yet.